News & Resources
The Cancer Immunotherapy Consortium embraces communication and collaboration among its members and among other like-minded associations that strive to bring effective immune-based cancer treatments to more patients.
CIC members contribute to the creation of white papers, response documents, and peer-reviewed publications advancing novel outcomes from workshops that seek practical solutions to today's challenges in cancer immunotherapy development.
We invite you to browse our library of publications, news releases, and e-newsletters.
CRI celebrates yesterday’s announcement of the first therapeutic cancer vaccine to receive approval from the U.S. Food and Drug Administration. The vaccine, called Provenge, is produced by Seattle biotech company Dendreon and is designed to treat certain forms of advanced prostate cancer.
April 30, 2010
CRI announced today that its program, the Cancer Vaccine Consortium—a leading global initiative on cancer vaccine research and development comprising industry, academia, and government institutions—has changed its name to the Cancer Immunotherapy Consortium (CIC).
March 18, 2010
CRI and the Association for Cancer Immunotherapy announce the launch of a global, broad-based initiative, called the MIATA Project to improve the reliability of reports of data derived from T cell-based immune monitoring assays, especially those used in the study of therapeutic vaccines for cancer and infectious diseases.
October 20, 2009